SCHEMBL23699136

SCHEMBL23699136

CC(C)(C)OC(=O)N1CC2(CCC(Nc3ccnc4ccc(F)cc34)C2)C1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
MET P08581 1/20 0.42
AXL P30530 1/20 0.42
CDK9 P50750 5/20 0.41
CCNT1 O60563 4/20 0.40
EHMT2 Q96KQ7 1/20 0.40
PIK3CD O00329 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC1 Q13547 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
ROCK2 O75116 1/20 0.39
CNR1 P21554 1/20 0.39
DNMT3A Q9Y6K1 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
PIK3CA P42336 1/20 0.38
FAAH O00519 1/20 0.37
MGLL Q99685 1/20 0.37
ABHD6 Q9BV23 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23699128 0.93 IDO1 (0.49) IDO1METAXLCDK9CCNT1
SCHEMBL30444709 0.93 IDO1 (0.49) IDO1METAXLCDK9CCNT1
SCHEMBL32674621 0.85 ROCK2 (0.42) IDO1ROCK2CCNCCDK8
SCHEMBL29862762 0.84 IDO1 (0.61) IDO1CDK9CCNT1EHMT2PIK3CD
SCHEMBL23360131 0.84 IDO1 (0.61) IDO1CDK9CCNT1EHMT2PIK3CD
SCHEMBL28834221 0.83 IDO1 (0.57) IDO1CDK9CCNT1PIK3CDCNR1
SCHEMBL28834220 0.83 IDO1 (0.57) IDO1CDK9CCNT1PIK3CDCNR1
SCHEMBL29933707 0.83 IDO1 (0.57) IDO1CDK9CCNT1PIK3CDCNR1
SCHEMBL23699133 0.81 IDO1 (0.53) IDO1CDK9CCNT1PIK3CDHDAC2
SCHEMBL21289908 0.81 IDO1 (0.47) IDO1CDK9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2026-02-17 US disclosed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US disclosed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551478-B2 Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity IDO2, IDO1, HDAC2 IDO1 2/4885MET 3439/4885AXL 4170/4885
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY IDO1, IDO2, INMT IDO1 1/4885MET 4254/4885AXL 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.